BioNTech Posts €531.9 Million Q1 Loss, Plans $1 Billion Buyback and Cuts 1,860 Jobs
BNTX•BioNTech reported Q1 2026 revenues of €118.1 million and a net loss of €531.9 million (adjusted €494.6 million), with diluted loss per share of €2.10 (adjusted €1.95). The company plans a $1 billion share buyback, will close German and Singapore sites impacting 1,860 jobs, advancing five pivotal pumitamig trials plus six late-stage readouts.
1. First Quarter Financial Results
BioNTech logged Q1 revenues of €118.1 million, down from €182.8 million year-on-year due to lower COVID-19 vaccine sales. Net loss widened to €531.9 million (adjusted loss €494.6 million) with diluted loss per share of €2.10 (adjusted €1.95), compared with a €415.8 million loss a year earlier.
2. Operational Restructuring and Job Cuts
The company will close manufacturing and research sites in Germany and Singapore, reducing its workforce by 1,860 positions. This consolidation aims to enhance operational efficiency and optimize its global manufacturing footprint.
3. Share Buyback Program and Financial Position
BioNTech launched a share repurchase plan of up to $1 billion over the next twelve months, backed by a cash and securities position of €16.8 billion. It reaffirmed full-year 2026 revenue guidance of €2.0–€2.3 billion to reflect seasonal COVID-19 vaccine demand.
4. Pipeline and Clinical Development Updates
Five additional pivotal trials for pumitamig have been initiated in partnership with Bristol Myers Squibb, while six late-stage data readouts are expected across immunomodulators, ADCs and mRNA cancer immunotherapies. Preparations for the 2026/2027 COVID-19 variant-adapted vaccine are also underway.
